GLP-1 Receptor Agonist APIs (Client Projects)
Diabetes, Obesity
Phase 3 / CommercialActive Manufacturing
Key Facts
Indication
Diabetes, Obesity
Phase
Phase 3 / Commercial
Status
Active Manufacturing
Company
About PolyPeptide Group
PolyPeptide is a world-leading CDMO for peptide APIs, leveraging over 70 years of experience since its founding in 1952. The company has manufactured over 1,000 peptides in GMP quality and serves a fast-growing market, particularly in metabolic diseases like diabetes and obesity. As a publicly traded company on the SIX Swiss Exchange, it maintains a broad project pipeline and is investing in capacity expansion to meet future demand.
View full company profile